CLINICAL TRIALS PROFILE FOR KIMMTRAK
✉ Email this page to a colleague
All Clinical Trials for KIMMTRAK
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT06070012 ↗ | Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma | Not yet recruiting | Immunocore Ltd | Phase 2 | 2024-06-30 | This is a phase II open-label, single-arm, multi-center study of tebentafusp in HLA- A*0201 positive previously untreated (1L) untreated metastatic uveal melanoma (mUM) with an integrated circulating tumor DNA (ctDNA) biomarker. |
NCT06070012 ↗ | Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma | Not yet recruiting | Diwakar Davar | Phase 2 | 2024-06-30 | This is a phase II open-label, single-arm, multi-center study of tebentafusp in HLA- A*0201 positive previously untreated (1L) untreated metastatic uveal melanoma (mUM) with an integrated circulating tumor DNA (ctDNA) biomarker. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for KIMMTRAK
Condition Name
Clinical Trial Locations for KIMMTRAK
Trials by Country
Clinical Trial Progress for KIMMTRAK
Clinical Trial Phase
Clinical Trial Sponsors for KIMMTRAK
Sponsor Name